PACRA upgrades Entity Ratings of Pharmagen Limited
Pharmagen Limited operates in a specific segment of the pharmaceutical industry: API (Active Pharmaceuticals Ingredients). This is mostly and predominantly fed through imports. Pharmagen Limited is a domestic player, claiming leading position amongst the local players which is not a large universe. Pharmagen Limited has built its profile over the year and serves some top players of the larger industry. The company has grown and augmented its position and is seen fortifying its production capabilities and product range. The able leadership has spearheaded the company’s strategy and operations. Lately the company has solicited interest of another big player from the local industry who has injected sizeable fresh equity into the company . This is diluting the financial burden and unlocking the hidden potential of the company. The growth prospects is sanguine. The management is focusing (a) process improvement (b) cost optimization (c) enriching product sweet. The control and governance prospects are continued to improve as a result of new prospects. The management intends to release reliance on funded facilities on need basis. The profitability and financial matters will improve gradually.
The ratings are dependent on success roll out of the envisaged strategy. The respective market position needs to be maintained and profitability must be aligned to the improving size. Any dilution in business on financial profile is unwarranted.
Pharmagen Limited is a public limited-unquoted Pharmaceutical company operating in Pakistan since 1990. The company is engaged in the manufacturing and sale of Pharmaceutical products and over the years it has become the leading producer of APIs (Active Pharmaceutical Ingredients) in Pakistan. Pharmagen in majority owned by Pervez Hussain’s family (44%), while other strategic partners include Rasheed Khan’s family (12%), Maj. Gen. (Retd.) Rahim Khan’s family along with Kashmir Education Foundation (17%), and Mr. Shamim Ahmed and his family (27%).